Article Text

Download PDFPDF
Metformin and placebo therapy in adjunct with lifestyle intervention both improve weight loss and insulin resistance in obese adolescents

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Paediatric Obesity Clinic in Germany


Adolescents aged 10 to 17years at risk of developing type 2 diabetes according to American Diabetes Association criteria who had enrolled in an individualised ‘lifestyle intervention’ weight loss programme (Phase 1). Candidates for the trial (phase 2) were those whose outcome in phase 1 at 6 months was classified unsuccessful; a reduction in body mass index (BMI) of <2 kg/m2 and persistent insulin resistance expressed as HOMA-IR (Homeostatic Model Assessment-estimated insulin resistance) > 3 or 95th percentile.


Metformin 500 mg twice per day or placebo for 6 months. Multiprofessional individualised lifestyle intervention continued throughout both phases of the study.


Improvement in insulin resistance (IR) measured by HOMA-IR after 6 months of treatment with Metformin/placebo.

HOMA-IR = fasting insulin × fasting glucose/22.5.

A clinically significant effect was defined as a decrease in HOMA-IR by 1.

Secondary …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.